Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01505530 · ClinicalTrials.gov registry record · Phase 2
A Phase 2 Study of LY2495655 in Participants With Pancreatic Cancer
A Phase 2 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 125
- Enrollment target
NCT01505530 is a Phase 2 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 125 participants.
The verdict
NCT01505530, a Phase 2 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 125 participants
- Enrollment target
Study Summary
This phase 2 study is a multicenter, randomized, double-blind, placebo-controlled trial in participants with locally advanced/inoperable or metastatic pancreatic cancer, and will investigate 2 different doses of LY2495655 in combination with standard of care chemotherapy.
Interventions
- DRUG Placebo
- DRUG Standard of Care Chemotherapy
- DRUG LY2495655
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 125 participants |
| Start Date | 2011-12 |
| Est. Completion | 2016-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01505530
The ClinicalTrials.gov registry entry for NCT01505530 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 125 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01505530 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01505530 about?
NCT01505530 is a clinical study titled "A Phase 2 Study of LY2495655 in Participants With Pancreatic Cancer". This phase 2 study is a multicenter, randomized, double-blind, placebo-controlled trial in participants with locally advanced/inoperable or metastatic pancreatic cancer, and will investigate 2 different doses of LY2495655 in combination with standard of care chemotherapy.
What is the current status of trial NCT01505530?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 125 participants. The study started on 2011-12. Estimated completion is 2016-01.
What interventions are being tested in trial NCT01505530?
The interventions under investigation include: Placebo (DRUG), Standard of Care Chemotherapy (DRUG), LY2495655 (DRUG).
Who is sponsoring clinical trial NCT01505530?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.